泊洛沙姆市场按形态、等级、分子量、应用和通路划分－2026-2032年全球预测

2025 年泊洛沙姆市场价值为 1.7729 亿美元，预计到 2026 年将成长至 1.9334 亿美元，年复合成长率为 9.03%，到 2032 年将达到 3.2486 亿美元。

关键市场统计数据
基准年 2025	1.7729亿美元
预计年份：2026年	1.9334亿美元
预测年份 2032	3.2486亿美元
复合年增长率 (%)	9.03%

对泊洛沙姆特性及其在製剂中发挥的跨领域作用进行综合概述，以影响创新重点和监管预期。

泊洛沙姆是双亲性嵌段共聚物，可解决众多工业和消费品应用中的配方难题。泊洛沙姆以其独特的增溶、乳化和热可逆凝胶特性而闻名，已被确立为从家用清洁剂到先进药物等各种配方中的基础辅料。本文将泊洛沙姆置于现代创新格局中，重点介绍其多功能性以及配方师对稳定性、生物相容性和可预测加工特性的不断变化的需求。

聚合物工程的进步、永续性以及数位化价值链如何重塑泊洛沙姆的价值提案

泊洛沙姆领域正经历一系列变革，这些变革是由技术、监管和商业性因素共同驱动的。聚合物工程的进步使得分子结构的精确设计成为可能，使配方师能够在不影响生物相容性的前提下，微调流变性能、增溶能力和释放动力学。同时，生物製药和新型给药平台的快速发展，推动了对能够在日益严格的加工和稳定性条件下保持性能稳定的辅料的需求。这些趋势正在促使人们重新评估整个价值链中的产品规格和分析控制。

关税变化对采购、配方策略和供应链韧性的影响正在重塑泊洛沙姆的采购决策。

2025年前后实施的关税政策调整的累积影响，为泊洛沙姆供应链带来了新的动态，其影响远不止于简单的成本压力。贸易措施迫使製造商和下游客户重新评估其筹资策略，从而显着加强了供应商多元化、尽可能选择近岸生产以及签订长期采购协议以确保供应连续性。这些策略性因应措施改变了采购前置作业时间，在某些情况下增加了库存持有量，并改变了生产商和买家之间的谈判动态。

细分市场层面的洞察，解释了应用需求、剂型、等级、分子量类别和通路结构如何影响策略组合决策。

细緻的細項分析揭示了需求驱动因素和技术要求如何因应用、剂型、等级、分子量和分销管道而异，从而塑造了泊洛沙姆产品线的独特商业化策略。就应用而言，家用和工业用户优先考虑清洁效果、泡沫控制和工艺稳定性，而个人护理配方师（尤其是在头髮、口腔和护肤领域）则要求感官体验细腻、性质温和且与活性成分相容。医药应用提出了最严格的要求：眼科、口服、注射和外用应用要求达到医药级性能、严格的杂质限度和有据可查的稳定性数据，这迫使供应商提供更完善的文檔和应用支援。

分子量区间（高分子量 >5000，中分子量 2000-5000，低分子量 <2000）反映了产品的性能和监管特性。高分子量材料适用于凝胶形成和缓释应用，中分子量材料适用于流变学控制，低分子量材料适用于快速溶解和感官影响最小的应用。分销通路特性（直销或经销商网路）决定了技术支援和供应连续性的提供方式。大规模製剂生产商倾向于直接交易，因为他们需要客製化的供应链和深入的技术合作。另一方面，分销商透过提供本地库存、快速交货和一体化物流服务，在服务小规模客户和区域市场方面发挥关键作用。了解这些细分市场层面的差异对于根据每个使用者群体的具体需求客製化产品开发、商业策略和客户支援至关重要。

主要区域在需求、监管要求和供应链策略方面的区域差异，将是决定每个目标区域商业性策略的根本因素。

了解泊洛沙姆产品的需求模式、法规要求和供应链结构，区域趋势至关重要。在美洲，强大的製药製造地和大规模的消费品生态系统，加上先进的分销基础设施，共同造就了高品质产品和可靠物流的需求。法规结构强调产品品质和可追溯性，该地区的买家通常优先考虑拥有完善认证和本地技术支援的供应商。

技术卓越、合规能力和以客户为中心的服务是泊洛沙姆供应商之间竞争的关键因素。

供应商之间的竞争格局主要体现在技术差异化、品质稳定性以及协助客户应对法规和配方挑战的能力。领先的製造商正投资于先进的品质系统、增强的分析能力和应用实验室，旨在为配方师提供可重复的性能和快速的故障排除支援。配方指导、稳定性测试通讯协定和客製化文件包等附加价值服务正逐渐成为差异化优势，尤其是在高价值的医药和个人护理领域。

针对製造商和供应商的实用策略倡议，旨在增强供应链韧性、推动永续性并巩固在泊洛沙姆市场的技术领先地位

产业领导者应采取一系列果断行动，将当今挑战转化为竞争优势。首先，优先考虑供应商多元化和短期紧急时应对计画，以降低贸易中断和关税波动带来的风险。建立关键等级产品的策略性库存缓衝，同时考虑本地生产和合约加工安排，以减少对跨境依赖。其次，投资配方科学和应用支援团队，与客户合作调整产品特性并优化浓度，以在原材料成本波动的环境下保持产品性能。

一项严谨的、依证的调查方法，结合了相关人员访谈、技术文献综述和供应链分析，得出了可操作的结论和建议。

本分析所依据的研究综合了多方面的证据，以确保提供可靠的实用见解。主要定性资料是透过对终端使用者产业的配方科学家、采购人员、品质保证专业人员和高级商务主管进行深度访谈收集的。这些访谈揭示了等级选择、监管文件和供应连续性方面面临的实际挑战，并提供了关税和区域趋势如何影响采购行为的第一手观点。

技术、监管和商业性动态的整合将决定泊洛沙姆生态系统中的竞争地位和未来机会。

这项分析凸显了泊洛沙姆作为多功能辅料的多重作用，其在消费品和製药领域的配方创新中扮演着日益重要的核心角色。客製化分子结构和环保生产方法的趋势正在重塑消费者对产品的预期，而日益严格的监管审查则要求提高分析透明度和供应链可追溯性。同时，贸易政策的变化正在加速供应商多元化、近岸外包以及流程效率提升等策略因应措施的实施，从而共同增强供应链的韧性。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按剂型分類的泊洛沙姆市场

• 液体
• 贴上
• 固态的

9. 泊洛沙姆市场（依等级划分）

• 泊洛沙姆188
• 泊洛沙姆338
• 泊洛沙姆407

第十章 以分子量分類的泊洛沙姆市场

• 高分子量（>5000）
• 低分子量（小于2000）
• 中等分子量（2000-5000）

第十一章 泊洛沙姆市场按应用领域划分

• 家用产品
• 工业的
• 个人护理
  • 护髮
  • 口腔清洁用品
  • 护肤
• 製药
  • 眼科
  • 口服
  • 肠外
  • 外用

第十二章 泊洛沙姆市场依通路划分

• 直接地
• 经销商

第十三章 泊洛沙姆市场区域划分

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 泊洛沙姆市集（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国泊洛沙姆市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章美国泊洛沙姆市场

第十七章：中国泊洛沙姆市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AkzoNobel NV
• Ashland Global Holdings Inc.
• BASF SE
• Clariant AG
• Croda International Plc
• Dow Inc.
• Evonik Industries AG
• Innospec Inc.
• Kao Corporation
• Lipo Chemicals Inc.
• Lubrizol Corporation
• Sigma-Aldrich Corporation
• Spectrum Chemical Manufacturing Corp.
• Stepan Company

The Poloxamer Market was valued at USD 177.29 million in 2025 and is projected to grow to USD 193.34 million in 2026, with a CAGR of 9.03%, reaching USD 324.86 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 177.29 million
Estimated Year [2026]	USD 193.34 million
Forecast Year [2032]	USD 324.86 million
CAGR (%)	9.03%

An integrated overview of poloxamer properties and cross-sector formulation roles shaping innovation priorities and regulatory expectations

Poloxamers are amphiphilic block copolymers that bridge multiple formulation challenges across a wide spectrum of industrial and consumer applications. Renowned for their unique solubilizing, emulsifying, and thermoreversible gelation properties, these materials have become foundational excipients in formulations ranging from household cleaners to advanced pharmaceuticals. The introduction situates poloxamers within the contemporary innovation landscape, underscoring their versatility and the evolving demands placed upon them by formulators seeking stability, biocompatibility, and predictable processing behavior.

Industry stakeholders increasingly expect excipients to deliver not only functional performance but also consistent quality, regulatory traceability, and sustainability credentials. As a consequence, manufacturers and end users have intensified collaboration around raw material specifications, in-process controls, and supply chain transparency. In parallel, formulation scientists continue to exploit poloxamer architecture to achieve targeted release profiles, enhanced bioavailability, and user-friendly sensory attributes in consumer products. This introduction frames the subsequent analysis by highlighting the interplay between material science advances, regulatory focus, and end-market application requirements that are shaping strategic priorities and innovation pipelines across sectors.

How advances in polymer engineering, regulatory scrutiny, sustainability priorities, and digital supply chains are reshaping poloxamer value propositions

The poloxamer landscape is undergoing a sequence of transformative shifts driven by converging technological, regulatory, and commercial forces. Advances in polymer engineering have enabled more precise tailoring of molecular architectures, which in turn allows formulators to fine-tune rheology, solubilization, and release kinetics without compromising biocompatibility. Simultaneously, the growth of biologics and novel delivery platforms has elevated the demand for excipients that perform predictably under increasingly stringent processing and stability conditions. These trends are prompting a re-evaluation of product specifications and analytical controls across the value chain.

Sustainability and green chemistry principles are reshaping procurement strategies and product claims. Companies are reassessing raw material sourcing, lifecycle impacts, and wastewater footprints, while suppliers explore cleaner production techniques and more efficient purification processes. Regulatory expectations are also intensifying; authorities are placing greater emphasis on excipient characterization, impurity profiling, and supply chain provenance. In response, the industry is adopting more robust documentation practices and deeper supplier audits to ensure compliance and to mitigate product risk.

At the commercial level, manufacturers and distributors are refining channel strategies to balance direct engagement with strategic partners. Digitalization of supply chain management and data exchange is accelerating transparency and responsiveness, enabling faster reaction to demand shifts and raw material disruptions. Collectively, these shifts are recalibrating how poloxamer value is delivered to end users, elevating the importance of formulation support, regulatory expertise, and sustainability attributes alongside traditional performance metrics.

Impacts of evolving tariff regimes on procurement, formulation strategy, and supply chain resilience that are reshaping poloxamer sourcing decisions

The cumulative effects of tariff policy adjustments implemented in and around 2025 have introduced new dynamics into the poloxamer supply chain that extend beyond immediate cost pressures. Trade measures have prompted manufacturers and downstream customers to reassess sourcing strategies, resulting in a pronounced emphasis on supplier diversification, nearshoring where feasible, and longer-term procurement contracts to secure continuity of supply. These strategic responses have altered procurement lead times, increased inventory carrying practices in some cases, and shifted negotiation dynamics between producers and buyers.

Tariff-driven cost volatility has also influenced formulation decisions. When raw material costs rise, development teams are incentivized to evaluate alternative grades, reformulate to reduce reliance on single ingredients, or optimize concentrations to preserve performance while managing input expense. In sectors with thin margins, distribution partners have played a mediating role, negotiating bulk purchases and offering tiered pricing arrangements to stabilize downstream pricing. At the same time, producers have accelerated investments in process efficiency and local production footprints to decrease exposure to international trade barriers.

Regulatory compliance and quality assurance have remained non-negotiable even as supply chain strategies evolve. Companies prioritizing regulatory-grade consistency have sought suppliers with robust quality certifications and traceable manufacturing documentation to maintain continuity in highly regulated applications such as parenteral pharmaceuticals. Ultimately, the tariff environment has catalyzed structural adjustments across sourcing, manufacturing, and commercial functions, encouraging greater resilience and strategic foresight without diminishing the central importance of product performance and regulatory integrity.

Segment-level intelligence describing how application demands, form factors, grades, molecular weight classes, and channel structures inform strategic portfolio decisions

A nuanced segmentation analysis reveals how demand drivers and technical requirements vary across application, form, grade, molecular weight, and distribution channel, shaping distinct commercialization strategies for poloxamer portfolios. In application terms, household care and industrial users prioritize cleaning efficacy, foam control, and process robustness, while personal care formulators, particularly in hair care, oral care, and skin care, demand sensory refinement, mildness, and compatibility with active ingredients. Pharmaceutical applications impose the strictest constraints; ophthalmic, oral, parenteral, and topical uses require pharmaceutical-grade performance, tight impurity limits, and documented stability profiles, compelling suppliers to provide enhanced documentation and application support.

Form preferences-liquid, paste, and solid-reflect both manufacturing practices and end-use considerations. Liquids often facilitate ease of metering and rapid incorporation in continuous processes, pastes are favored where concentrated handling reduces logistics costs, and solids support shelf-stable bulk handling and long-duration storage. Grade selection among Poloxamer 188, Poloxamer 338, and Poloxamer 407 correlates strongly with functional outcomes: lower molecular weight grades deliver distinct solubilization and wetting behavior, mid-range grades balance viscosity and thermal response, and higher-molecular-weight variants provide gelation and thickening functionality in specialty applications.

Molecular weight segmentation into high (>5000), medium (2000-5000), and low (<2000) categories informs both performance and regulatory characterization. High molecular weight materials are often chosen for gel-forming behavior and sustained-release roles, medium molecular weights provide balanced rheological control, and low molecular weights are selected for rapid dissolution and minimal sensory impact. Distribution channel dynamics-direct sales versus distributor networks-shape how technical support and supply continuity are delivered. Direct relationships are commonly pursued by large formulators requiring bespoke supply arrangements and deeper technical collaboration, while distributors play a pivotal role for smaller customers and regional markets by offering local inventory, rapid fulfillment, and bundled logistics services. Understanding these segment-level nuances is essential for aligning product development, commercial strategy, and customer support with the precise needs of each user cohort.

Regional differentiation in demand, regulatory expectations, and supply chain strategy that informs targeted commercial approaches across key geographies

Regional dynamics are central to understanding demand patterns, regulatory expectations, and supply chain configurations for poloxamer products. In the Americas, strong pharmaceutical manufacturing hubs and large consumer-packaged-goods ecosystems are paired with an advanced distribution infrastructure, creating demand for high-specification grades and reliable logistics. Regulatory frameworks emphasize product quality and traceability, and buyers in this region often prioritize suppliers with robust certifications and local technical support.

Europe, Middle East & Africa combine advanced regulatory regimes with heterogeneous market maturity across subregions. Western Europe leads in sustainability requirements and stringent excipient characterization, pushing suppliers to demonstrate lifecycle improvements and impurity control. Markets across the Middle East and Africa exhibit growing interest in personal care and industrial applications, though procurement patterns vary by local manufacturing capacity and import dependence. Across this broader region, companies benefit from flexible distribution partnerships that can bridge regulatory expectations with local commercial nuances.

Asia-Pacific represents both a major manufacturing base and a source of escalating demand across personal care and pharmaceutical segments. Rapid urbanization and rising healthcare investment are fostering increased R&D and local production capabilities, while suppliers in the region are innovating to meet cost-sensitive formulations without sacrificing quality. At the same time, supply chain decisions in this region are influenced by regional trade agreements, logistics infrastructure, and evolving regulatory alignment, encouraging both local sourcing strategies and selective importation of specialized grades. Collectively, these regional insights highlight the importance of tailored commercial approaches, locally relevant regulatory support, and strategic distribution models that respond to distinct buyer priorities and manufacturing footprints.

How technical excellence, compliance capabilities, and customer-centric services are defining competitive advantage among poloxamer suppliers

Competitive dynamics among suppliers center on technical differentiation, consistent quality, and the ability to support customers through regulatory and formulation challenges. Leading producers are investing in advanced quality systems, enhanced analytical capabilities, and application laboratories to provide formulators with reproducible performance and rapid troubleshooting support. Value-add services such as formulation guidance, stability testing protocols, and customized documentation packages have emerged as differentiators, particularly for high-value pharmaceutical and personal care accounts.

Strategic partnerships and long-term supply agreements have become more prevalent as manufacturers seek to secure continuity of supply and to co-develop specialty grades tailored to complex applications. Additionally, investments in capacity reliability and process improvements have been prioritized to reduce downtime and to ensure homogeneity of product batches. Companies with broader geographic footprints and integrated logistics networks can offer faster lead times and localized inventory, which is especially appealing to multinational customers balancing multiple production sites.

Sustainability and regulatory compliance are also shaping competitive positioning. Firms that can demonstrate cleaner production practices, reduced environmental impact, and transparent supply chains gain preferential consideration from both procurement and brand teams that face heightened scrutiny from regulators and consumers alike. In this environment, companies that combine technical excellence, regulatory rigor, and customer-centric services will be best positioned to deepen relationships and capture higher-value engagements across end markets.

Practical strategic initiatives for manufacturers and suppliers to build supply resilience, advance sustainability, and strengthen technical leadership in poloxamer markets

Industry leaders should adopt a set of decisive actions to convert contemporary challenges into competitive advantages. First, prioritize supplier diversification and near-term contingency planning to mitigate exposure to trade disruptions and tariff volatility. Establish strategic inventory buffers for critical grades while exploring localized manufacturing or tolling arrangements that reduce cross-border dependencies. Second, invest in formulation science and application support teams that can partner with customers to adapt product profiles and optimize concentrations, thereby preserving product performance under changing input-cost conditions.

Third, accelerate sustainability initiatives across the production lifecycle, targeting energy efficiency, solvent recovery, and wastewater treatment improvements that reduce environmental impact and align with evolving regulatory expectations. Fourth, enhance quality management systems and analytical transparency to meet the exacting needs of pharmaceutical and personal care customers; this includes expanded impurity profiling, stability dossiers, and supplier audit readiness. Fifth, refine distribution strategies by balancing direct relationships for large accounts with an empowered network of regional distributors to ensure responsiveness and local service.

Finally, strengthen commercial intelligence capabilities to anticipate regulatory changes, monitor raw material feedstock dynamics, and identify formulation-driven opportunities in high-growth application niches. By executing these actions, companies can fortify resilience, sustain technical leadership, and capture premium engagements while navigating the complexity of modern supply chains and regulatory environments.

A rigorous evidence-based methodology combining stakeholder interviews, technical literature review, and supply chain mapping to derive actionable insights and recommendations

The research underpinning this analysis integrated multiple evidence streams to ensure robust and pragmatic insights. Primary qualitative inputs were gathered through in-depth interviews with formulation scientists, procurement leaders, quality assurance professionals, and senior commercial executives across end-use sectors. These conversations illuminated practical challenges around grade selection, regulatory documentation, and supply continuity, and provided direct perspectives on how tariffs and regional dynamics influence procurement behavior.

Secondary research involved systematic review of technical literature, regulatory guidance documents, patent filings, and public disclosures related to polymer synthesis, excipient specifications, and manufacturing practices. Where appropriate, product technical data sheets and stability study summaries were analyzed to validate claims about performance characteristics and handling requirements. Supply chain mapping exercises identified typical sourcing routes, common risk nodes, and logistics dependencies that inform recommendations on diversification and nearshoring.

Analytical methods combined thematic synthesis with comparative benchmarking across application requirements and regional conditions. Findings were triangulated to reconcile technical performance considerations with commercial realities and regulatory constraints. Limitations of the methodology include variability in proprietary data access and the absence of confidential contract terms, which were mitigated by cross-validating stakeholder interviews and publicly available technical documentation. Overall, the approach prioritized actionable intelligence relevant to product developers, procurement teams, and executive decision-makers.

Synthesis of technical, regulatory, and commercial dynamics that determine competitive positioning and future opportunities in the poloxamer ecosystem

This analysis underscores the multifaceted role of poloxamers as versatile excipients that are increasingly central to formulation innovation across consumer and pharmaceutical sectors. Technical trends toward tailored molecular architectures and greener production methods are reshaping product expectations, while heightened regulatory scrutiny demands greater analytical transparency and supply chain traceability. Concurrently, trade policy shifts have accelerated strategic responses such as supplier diversification, nearshoring initiatives, and process efficiency investments that collectively strengthen supply resilience.

Segment-level realities reveal that application needs, form preferences, grade selection, molecular weight considerations, and distribution choices must be aligned to deliver optimal customer outcomes. Regional distinctions further emphasize the need for tailored commercial approaches that reflect local regulatory regimes, manufacturing capabilities, and buyer priorities. Companies that combine technical expertise, robust quality systems, and customer-centric services will be best positioned to convert current disruptions into opportunities for differentiation and long-term growth.

In sum, the poloxamer ecosystem is at a pivotal moment where strategic investments in sustainability, regulatory readiness, and supply chain agility will determine which players can sustain premium positioning and support the next generation of formulation innovations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Poloxamer Market, by Form

• 8.1. Liquid
• 8.2. Paste
• 8.3. Solid

9. Poloxamer Market, by Grade

• 9.1. Poloxamer 188
• 9.2. Poloxamer 338
• 9.3. Poloxamer 407

10. Poloxamer Market, by Molecular Weight

• 10.1. High (>5000)
• 10.2. Low (<2000)
• 10.3. Medium (2000-5000)

11. Poloxamer Market, by Application

• 11.1. Household Care
• 11.2. Industrial
• 11.3. Personal Care
  • 11.3.1. Hair Care
  • 11.3.2. Oral Care
  • 11.3.3. Skin Care
• 11.4. Pharmaceutical
  • 11.4.1. Ophthalmic
  • 11.4.2. Oral
  • 11.4.3. Parenteral
  • 11.4.4. Topical

12. Poloxamer Market, by Distribution Channel

• 12.1. Direct
• 12.2. Distributor

13. Poloxamer Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Poloxamer Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Poloxamer Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Poloxamer Market

17. China Poloxamer Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AkzoNobel N.V.
• 18.6. Ashland Global Holdings Inc.
• 18.7. BASF SE
• 18.8. Clariant AG
• 18.9. Croda International Plc
• 18.10. Dow Inc.
• 18.11. Evonik Industries AG
• 18.12. Innospec Inc.
• 18.13. Kao Corporation
• 18.14. Lipo Chemicals Inc.
• 18.15. Lubrizol Corporation
• 18.16. Sigma-Aldrich Corporation
• 18.17. Spectrum Chemical Manufacturing Corp.
• 18.18. Stepan Company

LIST OF FIGURES

• FIGURE 1. GLOBAL POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL POLOXAMER MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL POLOXAMER MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL POLOXAMER MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL POLOXAMER MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL POLOXAMER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL POLOXAMER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL POLOXAMER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL POLOXAMER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL POLOXAMER MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL POLOXAMER MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL POLOXAMER MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL POLOXAMER MARKET SIZE, BY PASTE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL POLOXAMER MARKET SIZE, BY PASTE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL POLOXAMER MARKET SIZE, BY PASTE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL POLOXAMER MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL POLOXAMER MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL POLOXAMER MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 188, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 188, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 188, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 338, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 338, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 338, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 407, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 407, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL POLOXAMER MARKET SIZE, BY POLOXAMER 407, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL POLOXAMER MARKET SIZE, BY HIGH (>5000), BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL POLOXAMER MARKET SIZE, BY HIGH (>5000), BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL POLOXAMER MARKET SIZE, BY HIGH (>5000), BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL POLOXAMER MARKET SIZE, BY LOW (<2000), BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL POLOXAMER MARKET SIZE, BY LOW (<2000), BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL POLOXAMER MARKET SIZE, BY LOW (<2000), BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL POLOXAMER MARKET SIZE, BY MEDIUM (2000-5000), BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL POLOXAMER MARKET SIZE, BY MEDIUM (2000-5000), BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL POLOXAMER MARKET SIZE, BY MEDIUM (2000-5000), BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL POLOXAMER MARKET SIZE, BY HOUSEHOLD CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL POLOXAMER MARKET SIZE, BY HOUSEHOLD CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL POLOXAMER MARKET SIZE, BY HOUSEHOLD CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL POLOXAMER MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL POLOXAMER MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL POLOXAMER MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL POLOXAMER MARKET SIZE, BY PERSONAL CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL POLOXAMER MARKET SIZE, BY PERSONAL CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL POLOXAMER MARKET SIZE, BY PERSONAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL POLOXAMER MARKET SIZE, BY HAIR CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL POLOXAMER MARKET SIZE, BY HAIR CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL POLOXAMER MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL POLOXAMER MARKET SIZE, BY ORAL CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL POLOXAMER MARKET SIZE, BY ORAL CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL POLOXAMER MARKET SIZE, BY ORAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL POLOXAMER MARKET SIZE, BY SKIN CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL POLOXAMER MARKET SIZE, BY SKIN CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL POLOXAMER MARKET SIZE, BY SKIN CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL POLOXAMER MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL POLOXAMER MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL POLOXAMER MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL POLOXAMER MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL POLOXAMER MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL POLOXAMER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL POLOXAMER MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL POLOXAMER MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL POLOXAMER MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL POLOXAMER MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL POLOXAMER MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL POLOXAMER MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL POLOXAMER MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL POLOXAMER MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL POLOXAMER MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL POLOXAMER MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL POLOXAMER MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL POLOXAMER MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL POLOXAMER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. AMERICAS POLOXAMER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 77. AMERICAS POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 78. AMERICAS POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 79. AMERICAS POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 80. AMERICAS POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 81. AMERICAS POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 82. AMERICAS POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 84. NORTH AMERICA POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 86. NORTH AMERICA POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 88. NORTH AMERICA POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 89. NORTH AMERICA POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 90. NORTH AMERICA POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 91. NORTH AMERICA POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. LATIN AMERICA POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 94. LATIN AMERICA POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 96. LATIN AMERICA POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 97. LATIN AMERICA POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 98. LATIN AMERICA POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 99. LATIN AMERICA POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 108. EUROPE POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. EUROPE POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 110. EUROPE POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 111. EUROPE POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 116. MIDDLE EAST POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 117. MIDDLE EAST POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 118. MIDDLE EAST POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 120. MIDDLE EAST POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 121. MIDDLE EAST POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 122. MIDDLE EAST POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 123. MIDDLE EAST POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 124. AFRICA POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 125. AFRICA POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 126. AFRICA POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 127. AFRICA POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 128. AFRICA POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 129. AFRICA POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 130. AFRICA POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 131. AFRICA POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 132. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 133. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 134. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 135. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 136. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 137. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 138. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 139. ASIA-PACIFIC POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL POLOXAMER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 141. ASEAN POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. ASEAN POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 143. ASEAN POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 144. ASEAN POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 145. ASEAN POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 146. ASEAN POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 147. ASEAN POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 148. ASEAN POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 149. GCC POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 150. GCC POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 151. GCC POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 152. GCC POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 153. GCC POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 154. GCC POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 155. GCC POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 156. GCC POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 157. EUROPEAN UNION POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 158. EUROPEAN UNION POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 159. EUROPEAN UNION POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 160. EUROPEAN UNION POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 161. EUROPEAN UNION POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 162. EUROPEAN UNION POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 163. EUROPEAN UNION POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 164. EUROPEAN UNION POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 165. BRICS POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 166. BRICS POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 167. BRICS POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 168. BRICS POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 169. BRICS POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 170. BRICS POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 171. BRICS POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 172. BRICS POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 173. G7 POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 174. G7 POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 175. G7 POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 176. G7 POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 177. G7 POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 178. G7 POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 179. G7 POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 180. G7 POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 181. NATO POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 182. NATO POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 183. NATO POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 184. NATO POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 185. NATO POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 186. NATO POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 187. NATO POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 188. NATO POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 189. GLOBAL POLOXAMER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 190. UNITED STATES POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 191. UNITED STATES POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 192. UNITED STATES POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 193. UNITED STATES POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 194. UNITED STATES POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 195. UNITED STATES POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 196. UNITED STATES POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 197. UNITED STATES POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 198. CHINA POLOXAMER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 199. CHINA POLOXAMER MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 200. CHINA POLOXAMER MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
• TABLE 201. CHINA POLOXAMER MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 202. CHINA POLOXAMER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 203. CHINA POLOXAMER MARKET SIZE, BY PERSONAL CARE, 2018-2032 (USD MILLION)
• TABLE 204. CHINA POLOXAMER MARKET SIZE, BY PHARMACEUTICAL, 2018-2032 (USD MILLION)
• TABLE 205. CHINA POLOXAMER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)